Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers

Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers Overview In a retrospective multi-center study involving 747 patients with advanced hepatocellular carcinoma (HCC) treated with a combination therapy of atezolizumab and bevacizumab, the influence of butyric acid-producing enterobacteria on treatment outcomes was investigated. Previous research has established a link between the gut

Remission of Renal Cell Carcinoma With Brain Metastases: A Case Study

Remission of Renal Cell Carcinoma With Brain Metastases: A Case Study Cases of complete remission of cancers with brain metastases are very rare. It’s often brought by tyrosine kinase inhibitor monotherapy in patients with metastatic renal cell carcinoma. For metastatic renal cell carcinoma (mRCC) patients, the case of brain metastasis has been

Renal Cell Carcinoma- Prognosis via Albumin Levels

Renal Cell Carcinoma- Prognosis via Albumin Levels Metastatic renal cell carcinoma (mRCC) - An Introduction Renal cell carcinoma (RCC) constitutes approximately 90% of all urologic malignancies. Approximately 30% of patients with RCC present with metastatic disease, and amongst those with localized disease, a substantial proportion will recur. Before 2005, immunotherapy with interleukin-2

Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers